QSS
AKBA icon

Quantitative Systematic Strategies’s Akebia Therapeutics AKBA Stock Holding History

Quantitative Systematic Strategies’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-18,732
Closed -$71K – 22
2021
Q2 		$71K Sell
18,732
-40,635
-68% -$137K 0.02% 440
2021
Q1 		$201K Buy
+59,367
New +$214K 0.03% 567
2020
Q4 		– Sell
-16,396
Closed -$41K – 602
2020
Q3 		$41K Sell
16,396
-12,561
-43% -$110K 0.01% 574
2020
Q2 		$393K Buy
28,957
+13,573
+88% +$140K 0.08% 358
2020
Q1 		$117K Buy
+15,384
New +$120K 0.1% 224
2019
Q1 		– Sell
-44,507
Closed -$246K – 385
2018
Q4 		$246K Buy
44,507
+21,582
+94% +$169K 0.06% 463
2018
Q3 		$202K Buy
+22,925
New +$205K 0.04% 528

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Quantitative Systematic Strategies's AKBA Position: Q3 2021 in Review

Quantitative Systematic Strategies sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 18,732 shares — an estimated $71K sold.

Quantitative Systematic Strategies first reported a position in AKBA in Q3 2018 and held it in 7 quarters. The position peaked at $393K in Q2 2020. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

  • Quantitative Systematic Strategies reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Quantitative Systematic Strategies sold 18,732 Akebia Therapeutics shares in Q3 2021, an estimated $71K.
  • Quantitative Systematic Strategies first reported a position in Akebia Therapeutics in Q3 2018 and held it in 7 quarters.
  • Quantitative Systematic Strategies's Akebia Therapeutics position peaked at $393K in Q2 2020.
  • 126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Quantitative Systematic Strategies's 13F filing for Q3 2021, filed 16 Nov 2021.